RedShiftBio Appoints Topbiox as Exclusive Distributor in China

Burlington, MA – May 7 2020, RedShift BioAnalytics, Inc. (RedShiftBio) announces its award winning AQS 3 ™pro, based on Microfluidic Modulation Spectroscopy (MMS) technology, is now available in China, following the appointment of Beijing-based Topbiox as exclusive distributor. Designed specifically for protein characterization applications in the biopharmaceutical industry, the technology has already seen wide adoption in the analytical toolkit of companies developing life-saving biotherapeutics and vaccines. This partnership will satisfy the growing demand for multi-functional, easy to use biophysical characterization tools for protein secondary structural analysis.

The Chinese biopharmaceutical industry has seen unprecedented growth over the past decade and continued expansion is predicted to result from a focus on biologics development, especially biosimilar mAb therapeutics and vaccines. RedShiftBio’s Microfluidic Modulation Spectroscopy-based AQS3pro allows biopharmaceutical companies to accelerate and de-risk their drug development pipelines with ultra-sensitive measurements of minute protein structural changes. These MMS novel capabilities have already led to rapid adoption by biopharmaceutical companies in Europe and North America.

The AQS3pro is a next-generation infrared technology with advanced data analytics to facilitate better, faster decision making in biopharmaceutical development from discovery to market. It provides direct measurement of previously undetectable changes in protein structural attributes critical to drug product efficacy and quality. The AQS3pro is designed specifically for the development, formulation and manufacture of Biotherapeutics.

“Topbiox is an experienced distributor of biophysical characterization tools in China. Its reputation for providing the highest quality instrumentation, service and applications support to its customers make it a perfect partner to us”, said Julien Bradley, CEO RedShiftBio.

Topbiox works closely with the Chinese biopharmaceutical industry to refine its instrumentation range to closely match industry requirements. It was looking to add a technique that enables teams to perform multiple secondary structure measurements on one instrument, without the need for specially qualified staff. The AQS3pro satisfies these demands. “This collaboration complements our existing products and enhances our protein characterization product line,” said Sean Shi, General Manager Topbiox. “With Microfluidic Modulation Spectroscopy, Chinese scientists can analyze their samples more efficiently and accurately. We are very excited to collaborate with RedShiftBio to provide our customers with the advanced AQS3pro.” The partnership means that Chinese scientists can now experience demonstrations and run samples onsite. Topbiox will be responsible for all sales, marketing, service and support.

If you would like to find out more about the AQS3pro then visit
https://redshiftbio.com/mms

Ends

About

RedShiftBio %u24C7 is a provider of innovative analytical instrumentation for the research, development and manufacture of protein therapeutic drugs. The company has developed a powerful new analytical technique, Microfluidic Modulation Spectroscopy (MMS) that enables direct probing of the biophysical structure of proteins. The patented MMS technology provides comprehensive secondary structure information across five key measurements, in a single automated analysis, replacing the requirement to run samples on multiple instruments. For further information, please visit www.redshiftbio.com/ or email info@redshiftbio.com

To find out more about RedShiftBio:
Please visit www.redshiftbio.com/collaboration , or email info@redshiftbio.com

For media enquiries in Europe
Contact:
Claire England
claire@covalentbonds.com
44 (0) 7808 020554

For media enquiries in the USA
Contact:
Laura Browne
laura@covalentbonds.com
1 978 893 9618